Who We Are
Frazier Life Sciences is a healthcare investment firm focusing on companies developing novel therapeutics. We have two core funds that enable investments across all stages of therapeutics companies:
Our Venture Funds primarily invest in private companies, focusing on company creation (over 30 companies formed since 2005) and Series A & B companies. We form true partnerships with distinctive entrepreneurs to build highly valuable companies and accelerate advancement of new therapeutic options for patients. Our latest Venture Fund is Frazier Life Sciences XI, a $987 million fund that was raised in 2022.
Our Public Funds provide capital to small- and mid-cap public biotech companies in financings, including follow-ons including CMPOs, PIPEs, IPOs, as well as supporting our companies in the open market. We partner with our public portfolio companies much as we do with our private portfolio companies. The Public Funds are investing over $1 billion of committed capital.
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
Carmot Therapeutics Enters into Definitive Merger Agreement with Rochelink
Frazier Life Sciences Welcomes Lauren Mifflin as Vice President of…
Frazier Life Sciences Welcomes Lauren Mifflin as Vice President of Company…link
Phathom Pharmaceuticals Announces Commercial Availability of…
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA®…link
Krystal Biotech Announces EMA Validation of Marketing Authorization…
Krystal Biotech Announces EMA Validation of Marketing Authorization…link
Our goal is to invest in therapeutics that ultimately benefit patients, and our portfolio has generated over 40 FDA approved therapeutics since 2010. Examples include:
Certain statements about Frazier Life Sciences made by portfolio company executives herein are intended to illustrate the work of Frazier’s team with such portfolio companies. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities, Senior Advisors, and/or investors in Frazier-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.